BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lang X, Liu Q, Fang H, Zhou Y, Forster MT, Li Z, Zhang X. The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia. Psychopharmacology (Berl) 2021;238:3643-52. [PMID: 34586464 DOI: 10.1007/s00213-021-05983-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Dai X, Li Y, Zhang Y, Ma J. Prevalence and factors associated of metabolic syndrome in first- treatment drug-naïve schizophrenia patients: a large-scale cross- sectional study.. [DOI: 10.21203/rs.3.rs-2662867/v1] [Reference Citation Analysis]
2 Zhu J, Wu J, Liu X, Ma J. Relationship between efficacy and common metabolic parameters in first-treatment drug-naïve patients with early non-response schizophrenia: a retrospective study. Ann Gen Psychiatry 2023;22:6. [PMID: 36800967 DOI: 10.1186/s12991-023-00436-3] [Reference Citation Analysis]
3 Boiko AS, Mednova IA, Kornetova EG, Goncharova AA, Semke AV, Bokhan NA, Ivanova SA. Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome. J Pers Med 2022;12. [PMID: 36294794 DOI: 10.3390/jpm12101655] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rødevand L, Tesli M, Andreassen OA. Cardiovascular disease risk in people with severe mental disorders: an update and call for action. Curr Opin Psychiatry 2022;35:277-84. [PMID: 35781467 DOI: 10.1097/YCO.0000000000000797] [Reference Citation Analysis]
5 Goh KK, Chen CY, Wu TH, Chen CH, Lu ML. Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction. Int J Mol Sci 2022;23. [PMID: 35806096 DOI: 10.3390/ijms23137092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yong N, Pan J, Li X, Yu L, Hou X. Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study. Eur J Med Res 2022;27:90. [PMID: 35690794 DOI: 10.1186/s40001-022-00706-y] [Reference Citation Analysis]
7 Mansuri Z, Makani R, Trivedi C, Adnan M, Vadukapuram R, Rafael J, Lodhi A, Reddy A. The role of metformin in treatment of weight gain associated with atypical antipsychotic treatment in children and adolescents: A systematic review and meta-analysis of randomized controlled trials. Front Psychiatry 2022;13:933570. [PMID: 36458118 DOI: 10.3389/fpsyt.2022.933570] [Reference Citation Analysis]
8 Zhu J, Wang H, Huang S, Zhang Y, Liu X, Li Y, Ma J. Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus. Front Psychiatry 2022;13:1034004. [PMID: 36329924 DOI: 10.3389/fpsyt.2022.1034004] [Reference Citation Analysis]